NEOS Investment Management LLC Boosts Stock Position in Humana Inc. (NYSE:HUM)

NEOS Investment Management LLC raised its stake in shares of Humana Inc. (NYSE:HUM) by 27.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,697 shares of the insurance provider’s stock after buying an additional 1,241 shares during the quarter. NEOS Investment Management LLC’s holdings in Humana were worth $1,445,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the 4th quarter worth about $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana in the fourth quarter worth approximately $30,000. LFA Lugano Financial Advisors SA grew its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana during the fourth quarter valued at approximately $33,000. Finally, Atwood & Palmer Inc. increased its position in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.37% of the stock is owned by company insiders.

Humana Stock Down 2.4 %

HUM opened at $263.95 on Friday. The stock has a market cap of $31.86 billion, a price-to-earnings ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm’s fifty day moving average is $270.14 and its 200 day moving average is $273.87. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HUM. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Barclays lifted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Eighteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.